Guinness Asset Management LTD Has Boosted Its Qualcomm (QCOM) Holding; Nektar Therapeutics (NKTR) Has 1.43 Sentiment

June 22, 2018 - By Ellis Scott

Nektar Therapeutics (NASDAQ:NKTR) Logo

Nektar Therapeutics (NKTR) investors sentiment increased to 1.43 in Q1 2018. It’s up 0.24, from 1.19 in 2017Q4. The ratio is positive, as 172 hedge funds started new or increased positions, while 120 sold and decreased their stakes in Nektar Therapeutics. The hedge funds in our database now own: 153.40 million shares, up from 150.36 million shares in 2017Q4. Also, the number of hedge funds holding Nektar Therapeutics in top ten positions was flat from 11 to 11 for the same number . Sold All: 23 Reduced: 97 Increased: 73 New Position: 99.

Guinness Asset Management Ltd increased Qualcomm Inc (QCOM) stake by 33.61% reported in 2018Q1 SEC filing. Guinness Asset Management Ltd acquired 13,890 shares as Qualcomm Inc (QCOM)’s stock declined 10.48%. The Guinness Asset Management Ltd holds 55,220 shares with $3.06M value, up from 41,330 last quarter. Qualcomm Inc now has $87.10 billion valuation. The stock decreased 0.07% or $0.04 during the last trading session, reaching $58.75. About 5.36M shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has risen 2.58% since June 22, 2017 and is uptrending. It has underperformed by 9.99% the S&P500. Some Historical QCOM News: 05/03/2018 – U.S. Republican senator backs review of Broadcom’s Qualcomm bid; 29/05/2018 – Qualcomm is expecting to meet this week with China’s antitrust regulators in a final push to secure clearance for its proposed $44 billion acquisition of NXP Semiconductors; 06/03/2018 – A secretive US national security committee has issued an unusual public warning against Broadcom’s proposed $142bn hostile takeover of San Diego-based Qualcomm, saying that a deal might lead to China overtaking the US in critical 5G technology; 09/03/2018 – Qualcomm: Jacobs Will No Longer Serve in an Executive Management Capacity; 16/03/2018 – CNBC Now: BREAKING: Qualcomm says Paul Jacobs will no be re-nominated to its board; it reached decision “following his; 14/03/2018 – Broadcom Drops Qualcomm Bid (Video); 06/03/2018 – ISS Says Qualcomm May Lose Shareholder Support on U.S. Probe; 16/03/2018 – NEW: Qualcomm board is meeting now and discussing fate of former CEO, chairman and current board member Paul Jacobs, Dow Jones reports; Jacobs indicated interest to Qualcomm’s board about taking the firm private, sources told CNBC; 17/04/2018 – QUALCOMM ANNOUNCES QUARTERLY CASH DIVIDEND; 05/03/2018 – Broadcom Reiterates Qualcomm Did Not Inform Its Own Stockholders or Broadcom of Its Secret, Voluntary Unilateral Request Filed on Jan 29, 2018

More notable recent QUALCOMM Incorporated (NASDAQ:QCOM) news were published by: Globenewswire.com which released: “Hagens Berman Alerts Investors in Qualcomm Incorporated (NASDAQ: QCOM) to the August 7, 2018 Securities Class …” on June 13, 2018, also Benzinga.com with their article: “Investors ‘Wait With Baited Breath’ Following Conflicting Reports On Qualcomm-NXP Deal” published on June 15, 2018, Globenewswire.com published: “SHAREHOLDER ALERT – EDGE GSUM MOH QCOM: The Law Offices of Vincent Wong Reminds Investors of …” on June 21, 2018. More interesting news about QUALCOMM Incorporated (NASDAQ:QCOM) were released by: Fool.com and their article: “Why Qualcomm’s New Snapdragon 850 Is Destined to Fail” published on June 17, 2018 as well as Nasdaq.com‘s news article titled: “A Safe Dividend Makes Verizon Communications Inc. Stock a Safe Bet” with publication date: June 19, 2018.

Guinness Asset Management Ltd decreased Noble Energy Inc (NYSE:NBL) stake by 88,000 shares to 266,925 valued at $8.09M in 2018Q1. It also reduced Newfield Expl Co (NYSE:NFX) stake by 39,200 shares and now owns 290,675 shares. Canadian Nat Res Ltd (NYSE:CNQ) was reduced too.

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.05, from 0.83 in 2017Q4. It turned negative, as 104 investors sold QCOM shares while 500 reduced holdings. 100 funds opened positions while 370 raised stakes. 1.11 billion shares or 0.11% less from 1.11 billion shares in 2017Q4 were reported. Td Asset Mgmt invested 0.08% in QUALCOMM Incorporated (NASDAQ:QCOM). Deprince Race Zollo Incorporated holds 509,094 shares. Eagle Ridge Invest owns 82,397 shares or 0.71% of their US portfolio. Commercial Bank Of Montreal Can reported 2.97M shares stake. Hanson Mcclain Inc accumulated 0% or 542 shares. Leavell Investment holds 0.12% in QUALCOMM Incorporated (NASDAQ:QCOM) or 18,236 shares. Iberiabank owns 6,119 shares. Amg Funds Llc accumulated 32,635 shares or 1.05% of the stock. Howe Rusling, a New York-based fund reported 718 shares. Bollard Group Lc holds 0% or 1,200 shares. The Massachusetts-based New England Private Wealth Advsr has invested 0.18% in QUALCOMM Incorporated (NASDAQ:QCOM). Eagleclaw Managment Lc stated it has 0.67% in QUALCOMM Incorporated (NASDAQ:QCOM). Stonebridge Advsrs Ltd Com reported 0.85% stake. Public Employees Retirement Sys Of Ohio accumulated 990,151 shares. Swiss Bancorp reported 0.32% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM).

Among 37 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 15 have Buy rating, 2 Sell and 20 Hold. Therefore 41% are positive. Qualcomm Inc. had 157 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was downgraded by Morgan Stanley on Thursday, November 10 to “Equal-Weight”. As per Wednesday, July 19, the company rating was maintained by Bernstein. RBC Capital Markets maintained it with “Buy” rating and $8000 target in Friday, April 13 report. On Wednesday, November 1 the stock rating was maintained by BMO Capital Markets with “Hold”. Argus Research maintained it with “Buy” rating and $73 target in Thursday, September 29 report. The company was upgraded on Monday, July 27 by Morgan Stanley. Citigroup initiated QUALCOMM Incorporated (NASDAQ:QCOM) on Wednesday, December 21 with “Neutral” rating. The firm earned “Buy” rating on Monday, March 26 by Susquehanna. UBS maintained QUALCOMM Incorporated (NASDAQ:QCOM) on Monday, November 6 with “Buy” rating. The rating was maintained by Canaccord Genuity on Monday, June 26 with “Buy”.

Since January 9, 2018, it had 0 insider buys, and 9 selling transactions for $7.68 million activity. $62,647 worth of QUALCOMM Incorporated (NASDAQ:QCOM) shares were sold by ROGERS ALEXANDER H. Another trade for 43,000 shares valued at $2.81M was made by GROB MATTHEW S on Tuesday, January 9. Shares for $618,603 were sold by Rosenberg Donald J. The insider THOMPSON JAMES H sold 50,126 shares worth $3.14 million. 16,082 QUALCOMM Incorporated (NASDAQ:QCOM) shares with value of $852,989 were sold by AMON CRISTIANO R.

Since January 1, 0001, it had 1 buy, and 34 sales for $90.80 million activity.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Fool.com which released: “Is Nektar Therapeutics Stock a Bargain Now?” on June 04, 2018, also Fool.com with their article: “Why Nektar Therapeutics Stock Stumbled 11.8% Today” published on June 08, 2018, Nasdaq.com published: “Here’s Why Nektar Therapeutics Jumped as Much as 17% Today” on June 06, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Seekingalpha.com and their article: “Nektar Therapeutics: In The Midst Of A Difficulty An Opportunity Arises” published on June 12, 2018 as well as Fool.com‘s news article titled: “Why Nektar Therapeutics, Ambac Financial Group, and Zuora Jumped Today” with publication date: June 01, 2018.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $9.58 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Price Capital Management Inc. holds 9.07% of its portfolio in Nektar Therapeutics for 43,004 shares. Duquesne Family Office Llc owns 1.19 million shares or 7% of their US portfolio. Moreover, First Light Asset Management Llc has 7% invested in the company for 300,086 shares. The New York-based Opus Point Partners Management Llc has invested 4.88% in the stock. Bridger Management Llc, a New York-based fund reported 668,492 shares.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $5.33 EPS, up 1,466.67% or $5.72 from last year’s $-0.39 per share. NKTR’s profit will be $913.62 million for 2.62 P/E if the $5.33 EPS becomes a reality. After $-0.60 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -988.33% EPS growth.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.